Myriad Genetics Standard Deviation
| MYGN Stock | | | USD 4.11 -0.92 -18.29% |
The Standard Deviation is a measure of how spread out the prices or returns of an asset are on average. It is the most widely used risk indicator in the field of investing and finance. Standard Deviation is commonly used to measure confidence in statistical conclusions regarding certain equity instruments or portfolios of equities. Below is Myriad Genetics's current Standard Deviation with peer comparisons and related risk metrics.
Current Standard Deviation Value
Myriad Genetics's Standard Deviation of 4.21 reflects elevated price variability. This places Myriad Genetics toward the higher end of the volatility range for Biotechnology.
Standard Deviation | = | SQRT(V) |
| = | 4.21 | |
Standard Deviation Peers Comparison
Relative to peers, Myriad Genetics's Standard Deviation is below the group average of 4.96. Peer readings range from 3.44 (Maravai Lifesciences Holdings) to 7.27 (Ginkgo Bioworks Holdings), reflecting moderate dispersion across the sector. Myriad Genetics has exhibited less price dispersion than the peer average over the measured period.
Standard Deviation Relative To Other Indicators
The chart below plots Standard Deviation against Maximum Drawdown for Myriad Genetics and its peers. Each point represents one equity — position along the horizontal axis shows Standard Deviation while the vertical axis shows Maximum Drawdown. Equities that cluster in different quadrants carry distinct risk-return profiles. Use the dropdowns to swap in other indicators for either axis.
Myriad Genetics shows nearly
3.81 of Maximum Drawdown per unit of Standard Deviation (
4.21 versus
16.04 ). This indicates Maximum Drawdown is significantly higher than Standard Deviation for Myriad Genetics.
Methodology, Assumptions & Data Sources
Myriad Genetics has a current Standard Deviation reading of 4.21. Standard Deviation for Myriad Genetics is derived by applying a defined formula to historical price observations, producing a time-series of comparable readings. Price data is sourced from standardized end-of-day feeds across supported exchanges, normalized for corporate actions. Myriad Genetics operates in the health care sector, which may exhibit distinct volatility and momentum characteristics relative to the broader market. Indicator accuracy depends on data continuity across the calculation period. Gaps in trading history may affect the output.
Other Technical Indicators